Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-05-19 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于持股5%以上股东权益变动达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding by a shareholder holding more than 5% of the company's shares, specifically a reduction in shareholding by Wei Xuening. It details the shareholding before and after the change, the method of reduction, and confirms no change in control or violation of regulations. The document is titled as a "提示性公告" (prompting announcement) regarding shareholding changes and does not contain financial statements or detailed financial analysis. It is a typical major shareholding notification as it reports a change crossing the 1% threshold for a significant shareholder. The document length is short (2721 characters), and it is not an annual or interim report, nor an earnings release or management report. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2023-05-19 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from CITIC Securities regarding the listing and circulation of restricted shares from the initial public offering of Changchun Baike Biotechnology Co., Ltd. It discusses the unlocking and circulation of restricted shares, shareholder commitments, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but rather a formal verification and compliance statement related to share circulation. This fits the category of a Regulatory Filing (RNS) as it is a regulatory compliance document and does not contain financial statements or detailed financial data.
2023-05-18 Chinese
长春百克生物科技股份公司首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is titled as an announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the dates, shareholder commitments, and includes a verification opinion from the sponsoring institution. The document is relatively short (2191 characters) and focuses on the announcement of the unlocking and circulation of restricted shares rather than presenting financial statements or detailed financial data. It does not contain financial results, management discussion, or audit information. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), as it concerns the change in share capital availability and circulation status.
2023-05-18 Chinese
长春百克生物科技股份公司2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2022 Annual General Meeting (AGM) Materials" for Changchun Baike Biotechnology Co., Ltd. It contains detailed agenda items for the 2022 AGM, including the Board of Directors' work report, Supervisory Board report, financial statements, profit distribution plan, financial budget, the full 2022 Annual Report and its summary, and proposals for reappointing auditing firms. The content includes meeting procedures, voting instructions, and detailed reports that are typically presented and discussed during an AGM. The document is lengthy (15,000 characters) and contains the actual meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2023-05-17 Chinese
长春百克生物科技股份公司关于参加网上集体业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an online collective earnings explanation meeting organized by regulatory and industry bodies. It details the meeting's date, time, platform, and the company's management who will participate in a Q&A session regarding the 2022 operating results. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the upcoming event and how to participate. The document length is short (1078 characters), and it serves as a notice for an investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on financial results discussion and investor interaction, but since it is an announcement of the event rather than the presentation content, it is closest to IP rather than a report or earnings release. Given the content and context, the classification is Investor Presentation (IP) with high confidence.
2023-05-12 Chinese
长春百克生物科技股份公司持股5%以上股东集中竞价减持计划完成暨减持结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from a company disclosing the completion of a major shareholder's share reduction plan. It details the shareholder's holdings before and after the reduction, the number of shares sold, the price range, and confirms that the plan has been fully implemented. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, specifically reporting on changes in significant share ownership levels crossing thresholds.
2023-05-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.